This page summarises and signposts to information about interactions with the COVID-19 vaccines

The vaccines and other medication

No interaction studies have been performed between COVID-19 vaccines and other medication.

See Using COVID-19 vaccines in patients with anticoagulation and bleeding disorders for use in individuals receiving anticoagulant therapy.

See Using COVID-19 vaccines in patients taking immunosuppressive medicines for use of COVID-19 vaccines in people receiving immunosuppressant therapy.

The vaccine and other vaccines

PHE COVID-19 Vaccination Programme Information for Healthcare Professionals and PHE Immunisation Against Infectious Disease (the Green Book) suggest interference between inactivated vaccines with different antigenic content is likely to be limited.  Therefore, based on experience with other vaccines, any potential problem is most likely to result in a slightly attenuated immune response to one of the vaccines. When administering more than one vaccine at the same time it becomes difficult to attribute any adverse effects to any particular product. There are no safety concerns.

Advice where patients recently receive another non-COVID-19 vaccine

PHE COVID-19 Vaccination Programme Information for Healthcare Professionals and PHE Immunisation Against Infectious Disease (the Green Book) advise COVID-19 vaccines are considered inactivated so eligible individuals should still be given the COVID-19 vaccine even if they have recently received another inactivated or live vaccine. This is to avoid any further delay in protection. The same applies for most other live and inactivated vaccines where COVID-19 vaccination has been received first or where a patient presents requiring two vaccines. An exception to this is the live attenuated shingles vaccine, where a 7 day interval should ideally be observed given the potential for an inflammatory response to COVID-19 vaccine to reduce the response to the live virus.

Studies are on-going to support co-administration of COVID-19 vaccines with influenza in the 2021-2022 season.

Where co-administration does occur, patients should be informed about the likely timing of potential adverse events relating to each vaccine.

The vaccine and COVID-19 treatments

PHE COVID-19 Vaccination Programme Information for Healthcare Professionals suggests that, as the COVID-19 vaccines are inactivated vaccines, COVID-19 treatments such as dexamethasone, convalescent plasma or monoclonal antibody treatment are not anticipated to contraindicate vaccine administration. Although theoretically, high levels of antibodies in the convalescent plasma could interfere with the immune response to the vaccine, passively acquired antibodies from the plasma treatment are not thought to persist for long, so by the time a person who has received this is well enough to receive a COVID-19 vaccination, these antibodies are likely to have gone.

In addition, as COVID-19 vaccines do not contain a live virus, response to vaccination will not be affected by anti-viral medication.

The vaccine “in-syringe” with other products

The manufacturer’s information for all COVID-19 vaccines state they should not be mixed in the same syringe as other products.

Change history

  1. Changes to reflect new advice regarding recommended interval between vaccines
  2. Published